Loading...
Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells
BCR-ABL(+) acute lymphoblastic leukemia patients have transient responses to current therapies. However, the fusion of BCR to ABL generates a potential leukemia-specific antigen that could be a target for immunotherapy. We demonstrate that the immune system can limit BCR-ABL(+) leukemia progression...
Na minha lista:
| Udgivet i: | J Immunol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4592825/ https://ncbi.nlm.nih.gov/pubmed/26378075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1501291 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|